miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.
TRAIL
cell death
colon cancer
miR-3132
miRNA
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
08
2021
accepted:
03
01
2022
entrez:
10
2
2022
pubmed:
11
2
2022
medline:
11
2
2022
Statut:
epublish
Résumé
TRAIL-based therapies are of significant clinical interest because of its unique ability to induce apoptosis in cancer cells while sparing normal and untransformed cells. This selective antitumor potential of the TRAIL pathway has been harnessed by development of therapeutics including recombinant (rh)TRAIL and TRAIL-receptor agonist antibodies such as mapatumumab and lexatumumab. While these TRAIL-based therapies have proven successful in preclinical studies and safe in early phase clinical trials, the limited serum half-life has been a hurdle for further clinical development. Here we characterize miR-3132, a novel and first-in class TRAIL-inducing miRNA with potent anti-proliferative and pro-apoptotic effects in cancer cell lines. Initial mechanistic studies indicate that miR-3132 engages the interferon signaling pathway to induce TRAIL and subsequent TRAIL-dependent apoptosis in cancer cell lines. Our data further suggests that the binding of miR-3132 to toll-like receptors could be the upstream pathway for the interferon response. The current study the first report to demonstrate miR-3132's
Types de publication
Journal Article
Langues
eng
Pagination
315-326Informations de copyright
AJCR Copyright © 2022.
Déclaration de conflit d'intérêts
None.
Références
Immunology. 2009 Jun;127(2):145-54
pubmed: 19476510
Cell Death Differ. 2014 Sep;21(9):1350-64
pubmed: 24948009
Expert Opin Ther Targets. 2015;19(9):1171-85
pubmed: 26004811
J Virol. 2005 Jul;79(14):9320-4
pubmed: 15994827
Mol Oncol. 2012 Dec;6(6):567-78
pubmed: 22902148
Cancer J. 2012 May-Jun;18(3):215-22
pubmed: 22647357
EMBO Mol Med. 2017 Jun;9(6):852
pubmed: 28572088
Biomed Res Int. 2014;2014:959461
pubmed: 25101302
Anticancer Res. 2006 Nov-Dec;26(6B):4115-24
pubmed: 17201122
RNA. 2013 Jun;19(6):737-9
pubmed: 23554231
Mol Cancer Ther. 2005 Dec;4(12):2026-36
pubmed: 16373718
RNA Biol. 2012 Jun;9(6):828-42
pubmed: 22617878
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Immunity. 2003 Jan;18(1):1-6
pubmed: 12530970
Nat Rev Mol Cell Biol. 2013 Aug;14(8):475-88
pubmed: 23800994
Cancer Biol Ther. 2012 Oct;13(12):1143-51
pubmed: 22892844
J Clin Invest. 1999 Jul;104(2):155-62
pubmed: 10411544
Adv Drug Deliv Rev. 2015 Jun 29;87:3-14
pubmed: 25979468
Acta Pharmacol Sin. 2019 Nov;40(11):1373-1385
pubmed: 31444476
J Immunol. 2002 Nov 1;169(9):4739-44
pubmed: 12391182
Nat Med. 1999 Feb;5(2):157-63
pubmed: 9930862
Exp Cell Res. 2000 Apr 10;256(1):58-66
pubmed: 10739652
Nat Rev Cancer. 2017 May 24;17(6):352-366
pubmed: 28536452